Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients
Authors
Stanisavljević, NatašaStojanovich, Ljudmila
Đoković, Aleksandra
Todić, Brankica
Dopsaj, Violeta
Saponjski, Jovica
Saponjski, Dušan
Marković, Olivera
Belizna, Cristina
Zdravković, Marija
Marisavljević, Dragomir
Article (Published version)
Metadata
Show full item recordAbstract
Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated ...to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.
Keywords:
inflammation / Biomarkers / antiphospholipid syndrome / Antiphospholipid Syndrome / arginine / Arginine / biological marker / C reactive protein / C-Reactive Protein / complication / Dilatation, Pathologic / Endothelium, Vascular / glyceryl trinitrate / human / Humans / lesions and defects / lupus erythematosus / N,N-dimethylarginine / Nitroglycerin / systemic / thrombosis / Thrombosis / vascular endothelium / vasodilatation / VasodilationSource:
International Journal of Molecular Sciences, 2022, 23, 20Publisher:
- MDPI
Funding / projects:
- A multidisciplinary study of the role of genetic and acquired autoimmune abnormalities in the onset of systemic manifestations of antiphospholipid syndrome. (RS-MESTD-Basic Research (BR or ON)-175041)
- Development of multivariable methods for analytical support to biomedical diagnostics (RS-MESTD-Technological Development (TD or TR)-32040)
- Biomarkers of organ damage and dysfunction (RS-MESTD-Basic Research (BR or ON)-175036)
DOI: 10.3390/ijms232012309
ISSN: 1661-6596
WoS: 000873075300001
Scopus: 2-s2.0-85140815846
Collections
Institution/Community
PharmacyTY - JOUR AU - Stanisavljević, Nataša AU - Stojanovich, Ljudmila AU - Đoković, Aleksandra AU - Todić, Brankica AU - Dopsaj, Violeta AU - Saponjski, Jovica AU - Saponjski, Dušan AU - Marković, Olivera AU - Belizna, Cristina AU - Zdravković, Marija AU - Marisavljević, Dragomir PY - 2022 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4310 AB - Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction. PB - MDPI T2 - International Journal of Molecular Sciences T1 - Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients VL - 23 IS - 20 DO - 10.3390/ijms232012309 ER -
@article{ author = "Stanisavljević, Nataša and Stojanovich, Ljudmila and Đoković, Aleksandra and Todić, Brankica and Dopsaj, Violeta and Saponjski, Jovica and Saponjski, Dušan and Marković, Olivera and Belizna, Cristina and Zdravković, Marija and Marisavljević, Dragomir", year = "2022", abstract = "Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.", publisher = "MDPI", journal = "International Journal of Molecular Sciences", title = "Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients", volume = "23", number = "20", doi = "10.3390/ijms232012309" }
Stanisavljević, N., Stojanovich, L., Đoković, A., Todić, B., Dopsaj, V., Saponjski, J., Saponjski, D., Marković, O., Belizna, C., Zdravković, M.,& Marisavljević, D.. (2022). Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients. in International Journal of Molecular Sciences MDPI., 23(20). https://doi.org/10.3390/ijms232012309
Stanisavljević N, Stojanovich L, Đoković A, Todić B, Dopsaj V, Saponjski J, Saponjski D, Marković O, Belizna C, Zdravković M, Marisavljević D. Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients. in International Journal of Molecular Sciences. 2022;23(20). doi:10.3390/ijms232012309 .
Stanisavljević, Nataša, Stojanovich, Ljudmila, Đoković, Aleksandra, Todić, Brankica, Dopsaj, Violeta, Saponjski, Jovica, Saponjski, Dušan, Marković, Olivera, Belizna, Cristina, Zdravković, Marija, Marisavljević, Dragomir, "Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients" in International Journal of Molecular Sciences, 23, no. 20 (2022), https://doi.org/10.3390/ijms232012309 . .